Please visit answersincme.com/BCJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses JAK inhibitor therapy for patients with myelofibrosis. Upon completion of this activity, participants should be better able to: Identify early signs of ruxolitinib failure for timely risk stratification of patients with myelofibrosis (MF); Describe the clinical profiles of novel JAK inhibitors for the treatment of patients with MF; and Outline evidence-based strategies to optimize JAK inhibitor therapy for patients with MF.

John O. Mascarenhas, MD - Optimizing JAK Inhibitor Therapy for Patients With Myelofibrosis: Integrating New and Emerging Therapies Into the Current Treatment Paradigm

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device.  Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

Science

Medicine

Health & Fitness

Life Sciences

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology &amp; Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device.  Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

Share John O. Mascarenhas, MD - Optimizing JAK Inhibitor Therapy for Patients With Myelofibrosis: Integrating New and Emerging Therapies Into the Current Treatment Paradigm

Sign up to save your podcasts

John O. Mascarenhas, MD - Optimizing JAK Inhibitor Therapy for Patients With Myelofibrosis: Integrating New and Emerging Therapies Into the Current Treatment Paradigm

John O. Mascarenhas, MD - Optimizing JAK Inhibitor Therapy for Patients With Myelofibrosis: Integrating New and Emerging Therapies Into the Current Treatment Paradigm

More shows like CME in Minutes: Education in Oncology & Hematology

Planet Money

Journal of Clinical Oncology (JCO) Podcast

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

This Week in Cardiology

Oncology Today with Dr Neil Love

CCO Oncology Podcast

CME in Minutes: Education in Dermatology

Oncology Brothers: Practice-Changing Cancer Discussions

CME in Minutes: Education in Ophthalmology

CME in Minutes: Education in Cardiology & Pulmonology

CME in Minutes: Education in Primary Care

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases